Australian advocates push for subsidised GLP-1 drugs to treat PMOS

Women with polycystic metabolic ovarian syndrome—a chronic hormonal condition affecting one in eight Australian women—are being denied access to weight-loss medications that could help manage their symptoms, patient advocates say, because the drugs remain unsubsidized and cost several hundred dollars a month out of pocket.

The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia is pushing for GLP-1 drugs to be added to the Pharmaceutical Benefits Scheme, the government program that subsidizes medications for eligible Australians. The condition, formerly called polycystic ovarian syndrome, produces irregular periods, excess facial and body hair, weight gain, and hair thinning. It has no cure. Left untreated, it increases the risk of type 2 diabetes, cardiovascular disease, and endometrial cancer. Doctors currently prescribe GLP-1 medications off-label for PMOS patients—meaning the drugs are approved for other uses but not specifically for this condition—yet the Therapeutic Goods Administration has not formally approved them for treating it.

Lorna Berry, a spokesperson for the patient advocacy group who received her diagnosis at 32, told the Guardian that subsidized access would be transformative. "It's important for people to have access to medications, irrespective of where they live or where they were born," she said. "It's really important that there's equitable access." She noted that the current cost structure already excludes some women from treatment entirely. A University of New South Wales study published in July found that roughly half a million Australians are using weight-loss medications regularly, yet many cannot afford them without government support.

The medical establishment remains cautious. Magdalena Simonis, associate professor and women's health spokesperson for the Royal Australasian College of Physicians, said the college has not yet taken a position on whether GLP-1s are appropriate for managing PMOS. "They're not necessarily the only tool we have available to us, and that is important because long-term use is expensive, and it doesn't look like these are going to be on the PBS anytime soon, and maybe not ever for conditions such as PMOS," Simonis said. She pointed to a pattern: "Because traditionally women's conditions are not included in these changes." Simonis, a GP with specialized expertise in PMOS, suggested that if research demonstrates these medications outperform existing treatments, a broader conversation about health equity would become necessary.

GLP-1 drugs work by mimicking a naturally occurring hormone that regulates blood sugar and suppresses appetite. Ozempic, which contains the active ingredient semaglutide, is already listed on the PBS but only for diabetes treatment. Wegovy, which contains the same ingredient at a higher dose, was recommended for PBS subsidy by the Pharmaceutical Benefits Advisory Committee in November for patients with a body mass index above 35. The committee is scheduled to meet next month to consider Novo Nordisk's revised proposal for Wegovy coverage following extended negotiations with the Department of Health.

QENDO, another advocacy organization focused on PMOS and women's health conditions, acknowledged the growing interest in GLP-1s for managing metabolic complications in PMOS but urged caution. "While emerging evidence suggests potential benefits for some patients, further research is needed to establish their long-term effectiveness and safety specifically for PMOS," said Kate Fisher, the organization's acting chief executive. The question now is whether the government will move to subsidize these medications for a condition that affects millions of Australian women, or whether cost and bureaucratic inertia will continue to limit access to those who can afford to pay.